653 related articles for article (PubMed ID: 21498564)
1. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
[TBL] [Abstract][Full Text] [Related]
2. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.
Davis JH; Aperlo C; Li Y; Kurosawa E; Lan Y; Lo KM; Huston JS
Protein Eng Des Sel; 2010 Apr; 23(4):195-202. PubMed ID: 20299542
[TBL] [Abstract][Full Text] [Related]
3. Engineering of stable bispecific antibodies targeting IL-17A and IL-23.
Mabry R; Lewis KE; Moore M; McKernan PA; Bukowski TR; Bontadelli K; Brender T; Okada S; Lum K; West J; Kuijper JL; Ardourel D; Franke S; Lockwood L; Vu T; Frank A; Appleby MW; Wolf A; Reardon B; Hamacher NB; Stevens B; Lewis P; Lewis KB; Gilbertson DG; Lantry M; Julien SH; Ostrander C; Chan C; Byrnes-Blake K; Brody J; Presnell S; Meengs B; Levin SD; Snavely M
Protein Eng Des Sel; 2010 Mar; 23(3):115-27. PubMed ID: 20022918
[TBL] [Abstract][Full Text] [Related]
4. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
[TBL] [Abstract][Full Text] [Related]
5. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
Gu J; Ghayur T
Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
[TBL] [Abstract][Full Text] [Related]
6. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
[TBL] [Abstract][Full Text] [Related]
7. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
[TBL] [Abstract][Full Text] [Related]
8. PH1-derived bivalent bibodies and trivalent tribodies bind differentially to shed and tumour cell-associated MUC1.
Schoonooghe S; Burvenich I; Vervoort L; De Vos F; Mertens N; Grooten J
Protein Eng Des Sel; 2010 Sep; 23(9):721-8. PubMed ID: 20616115
[TBL] [Abstract][Full Text] [Related]
9. EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies.
Cooke HA; Arndt J; Quan C; Shapiro RI; Wen D; Foley S; Vecchi MM; Preyer M
MAbs; 2018; 10(8):1248-1259. PubMed ID: 30215570
[TBL] [Abstract][Full Text] [Related]
10. Isolation of a human anti-epidermal growth factor receptor Fab antibody, EG-19-11, with subnanomolar affinity from naïve immunoglobulin repertoires using a hierarchical antibody library system.
Hur BU; Yoon JB; Liu LK; Cha SH
Immunol Lett; 2010 Nov; 134(1):55-61. PubMed ID: 20797408
[TBL] [Abstract][Full Text] [Related]
11. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
Vincent KJ; Zurini M
Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
[TBL] [Abstract][Full Text] [Related]
12. Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies.
Skegro D; Stutz C; Ollier R; Svensson E; Wassmann P; Bourquin F; Monney T; Gn S; Blein S
J Biol Chem; 2017 Jun; 292(23):9745-9759. PubMed ID: 28450393
[TBL] [Abstract][Full Text] [Related]
13. Stability engineering of scFvs for the development of bispecific and multivalent antibodies.
Miller BR; Demarest SJ; Lugovskoy A; Huang F; Wu X; Snyder WB; Croner LJ; Wang N; Amatucci A; Michaelson JS; Glaser SM
Protein Eng Des Sel; 2010 Jul; 23(7):549-57. PubMed ID: 20457695
[TBL] [Abstract][Full Text] [Related]
14. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
15. Constant domain-exchanged Fab enables specific light chain pairing in heterodimeric bispecific SEED-antibodies.
Dietrich S; Gross AW; Becker S; Hock B; Stadlmayr G; Rüker F; Wozniak-Knopp G
Biochim Biophys Acta Proteins Proteom; 2020 Jan; 1868(1):140250. PubMed ID: 31295556
[TBL] [Abstract][Full Text] [Related]
16. The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody.
Lu D; Jimenez X; Witte L; Zhu Z
Biochem Biophys Res Commun; 2004 May; 318(2):507-13. PubMed ID: 15120630
[TBL] [Abstract][Full Text] [Related]
17. [Bispecific antibodies: what future?].
Pèlegrin A; Robert B
Med Sci (Paris); 2009 Dec; 25(12):1155-8. PubMed ID: 20035697
[TBL] [Abstract][Full Text] [Related]
18. Structural understanding of stabilization patterns in engineered bispecific Ig-like antibody molecules.
Jordan JL; Arndt JW; Hanf K; Li G; Hall J; Demarest S; Huang F; Wu X; Miller B; Glaser S; Fernandez EJ; Wang D; Lugovskoy A
Proteins; 2009 Dec; 77(4):832-41. PubMed ID: 19626705
[TBL] [Abstract][Full Text] [Related]
19. Engineering antibodies for stability and efficient folding.
Honegger A
Handb Exp Pharmacol; 2008; (181):47-68. PubMed ID: 18071941
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]